INTRODUCTION
Coccidiosis continues to be one of the most important infectious diseases of chickens around the world (Williams, 1999; Smith and Helm, 2008) . Subclinical coccidiosis, characterized by weight loss, reduced weight gain, poor feed efficiency, and lack of overt clinical symptoms, is the commonly occurring form of coccidiosis (Williams, 1999 (Williams, , 2005 . The use of vaccines for the control of coccidiosis has become increasingly C 2017 Poultry Science Association Inc. Received December 2, 2016. Accepted January 18, 2017. This publication is a contribution of the Mississippi Agricultural and Forestry Experiment Station. This material is based upon work supported by the National Institute of Food and Agriculture, U.S. Department of Agriculture, Hatch project under accession number 322290. Use of trade names in this publication does not imply endorsement by Mississippi Agricultural and Forestry Experiment Station of these products, nor similar ones not mentioned. 1 Corresponding author: d.peebles@msstate.edu common in the United States, primarily due to pressure to reduce or remove subtherapeutic antibiotics and ionophores from poultry diets in many parts of the world, and the resistance of Eimeria parasites to available in-feed chemical anti-coccidials (McEvoy, 2001; Williams, 2002 Williams, , 2005 . As a result, many producers are looking for ways to maximize the protective effect provided by coccidiosis vaccines against coccidiosis infection. Due to the relatively short life span of the broiler chicken, early vaccination by spray or in ovo application is a practicable method of controlling coccidiosis because it allows for an early development of protective immunity against an infection. In ovo vaccination of embryos with live coccidia parasites involves the controlled delivery of a precise dose of Eimeria oocysts to each embryo (Williams, 2002) .
Although vaccination with live non-attenuated coccidia oocysts has become widely accepted, some reports have indicated that these vaccinations can affect early broiler growth performance. These reports suggest that under commercial conditions, temporary reductions in 2546 BW gain (BWG) and feed efficiency between 14 and 28 d post hatch (dph) can occur due to either the direct effect of the live oocysts vaccine, or indirectly by other infectious diseases such as necrotic enteritis that is associated with coccidiosis infection (Chapman et al., 2002; Williams, 2002; Williams, 2005; Lehman et al, 2009 ). Certain studies have examined the effect of vaccination on performance and recovery from loss in performance during the mid to late growth stages of the broiler (Mathis, 1999; Mathis and Lang, 2001) . However, only a few studies have examined the effects of coccidiosis vaccination on performance during the life of the broiler immediately following hatch, and during the peak of the first coccidial cycling and oocyst shedding (Weber et al., 2004) .
The objective of this current study was to evaluate the growth performance [feed intake (FI), BWG, and feed efficiency] of broiler chickens during the first 14 dph of vaccine-derived oocyst shedding, without being concurrently challenged with an Eimeria infection. The birds that were evaluated for their performance in this study had been previously vaccinated with the EM1 vaccine via in ovo injection at 18.5 d of incubation (doi) and showed oocyst shedding from zero to 14 dph (Sokale et al., 2017) . This is the first study that describes the performance characteristics of Ross 708 broilers during the first 14 dph of oocyst shedding following an in ovo vaccination with the commercially available Inovocox EM1 (EM1) vaccine.
MATERIALS AND METHODS

General
This study was conducted according to a protocol approved by the Institutional Animal Care and Use Committee of Mississippi State University. A total of 2,520 broiler hatching eggs (Ross 708) collected from a commercial breeder flock at 48 wk of age was held for 2 d under standard storage conditions after collection. Prior to setting, eggs were individually weighed and only eggs that had normal appearance and that weighed within 10% of the mean weight of all eggs (60 ± 6.0 g) were set (Pulikanti et al., 2012) . A total of 1,764 eggs was incubated under standard conditions (Peebles and Brake, 1987; Zhai et al., 2011 ) in a Jamesway model PS 500 setter unit (Jamesway Incubator Company Inc., Cambridge, Ontario, Canada). There were 28 treatment-replicate groups (4 treatment groups on each of 7 replicate tray levels), with each containing 63 eggs, arranged in the setter. At 18 doi, eggs were candled to remove those that were unfertilized or contained dead embryos as described by Ernst et al. (2004) . At 18.5 doi, eggs were injected according to one of the 4 treatments specified below.
Experimental Design
Eggs were injected using an Embrex Inovoject injector system (Zoetis Animal Health, Research Triangle Park, NC). The methodology for confirmation of site of injection, egg handling, and the injection procedure was as described in detail by Sokale et al. (2017) . Briefly, EM1 vaccine was reconstituted in sterile commercial Marek's Disease vaccine diluent (Merial Co., Duluth, GA) and administered at a rate of 50 μL per egg at 18.5 doi. The number of oocysts contained per dose administered into each individual embryonated egg was determined in a previous study (Sokale et al., 2017) . A total of 375 oocysts from each of the acervulina, maxima, and tenella species of Eimeria was injected into each individual embryonated egg. Treatments included non-injected, dry-punch (eggs subjected to injection process without delivery of diluent), and diluent-injected (eggs subjected to injection process with delivery of 50 μL of commercial diluent) controls. All eggs were subsequently transferred to a Jamesway model PS 500 hatcher unit (Jamesway Incubator Company Inc., Cambridge, Ontario, Canada), in which eggs in their respective treatment-replicate groups were assigned hatcher basket positions that corresponded to their arrangement in the setter.
Data Collection
At 21 doi, a total of 20 straight-run chicks out of those that hatched from the 63 eggs incubated in each of the 28 treatment-replicate groups was randomly selected and subsequently evaluated for performance. After selection, the chicks were wing-banded, weighed, and placed in each of 28 isolated wire-floored battery cages of a light-controlled research facility. Chicks were placed in the battery cages using the same experimental design that was used for the arrangement of eggs in the hatcher unit. Pen conditions, including brooding environment, were monitored twice daily throughout the grow-out period to ensure their conformity to commercial standards. Chicks were given feed and water ad libitum for 14 dph. All birds were fed a standard Mississippi State University broiler basal starter diet formulated to meet or exceed NRC (1994) recommendations throughout the 14 dph period. Although housed in the same facility and under the same conditions, the groups that did not receive vaccine were kept separately from the vaccinated groups to reduce the risk of crosscontamination (Sokale et al., 2017) . Bird numbers, BW, and feed weights were determined for each pen on a weekly basis from zero to 14 dph. Furthermore, BWG, FI, feed conversion ratio (FCR), and percentage mortality were determined for the zero to 7, 7 to 14, and zero to 14 dph intervals.
Statistical Description
A randomized complete block design was used during the incubation and grow-out periods. Treatment was viewed as a fixed effect and block (tray level) as a random effect in the one-way ANOVA of absolute BW, weekly BWG, FI, FCR, and percentage mortality. All variables were analyzed using the MIXED procedure of SAS software 9.3 (SAS institute, 2012). Least-square means were compared in the event of significant global effects. Global and least-square means differences were considered significant at P ≤ 0.05.
RESULTS AND DISCUSSION
The performance characteristics of broiler chickens that were administered the EM1 vaccine at 18.5 doi were determined during the first 14 dph of oocyst shedding. This performance evaluation was conducted in order to determine any possible effects of the vaccine on broiler performance during the first events of coccidial cycling and oocyst shedding. The duration of the first cycle of Eimeria development can take up to 7 d, depending on the pre-patent period of the Eimeria spp (Chapman et al., 2002) . In a previous companion study (Sokale et al., 2017) , it was shown that in ovo injection of the EM1 vaccine led to coccidial cycling and oocyst shedding commonly observed in the normal life cycle of Eimeria subsequent to a natural coccidiosis infection. The ordinary developmental stages of the Eimeria parasite were observed, including the shedding of oocysts in the feces, with peak oocyst shedding observed at 7 and 10 dph following the administration of the EM1 vaccine containing 3 Eimeria spp (E. acervulina, E. maxima, and E. tenella).
The results of this study indicated that mortality in the zero to 7 and 7 to 14 dph intervals as well as cumulative (zero to 14 dph) percentage mortality were not significantly affected by treatment. Mean cumulative percentage mortality values for birds in the non-injected, dry-punch, and diluent-injected control groups, and in the vaccine-injected treatment group are presented in Figure 1 . The observance of similar cumulative percentage mortality results for the non-injected control and vaccine-injected treatment groups establish that broiler chick livability was not affected by the dose or time of administration of the EM1 vaccine suspended in commercial diluent.
There was also no significant (P = 0.509) effect due to treatment on mean BW at zero dph (Table 1 ). The lack of an effect on hatchling BW indicates that embryonic growth during the last 2.5 doi was not affected by the in ovo administration of commercial diluent that did or did not contain the EM1 vaccine. Bello et al. (2013) reported that in comparison to a non-injected control group, the in ovo injection of 100 μL of commercial diluent significantly reduced the percentage hatchability of fertilized eggs at 21.0 doi, but analogous to the current study, observed that the yolk-free BW of the hatchlings was not significantly affected. Furthermore, in that report and in a subsequent companion report (Bello et al., 2014) , it was shown that in comparison to broilers belonging to a non-injected control group, those that were hatched from eggs that received the in ovo injection of 100 μL of commercial diluent did not experience a significant change in hatching body length or total BW. Conversely, Zhai et al. (2011) showed that although the in ovo injection of 1.2 mL of physiological saline did not affect the internal temperature of embryonated broiler hatching eggs between 6 and 22 h after injection, it significantly increased relative (percentage of set egg weight) embryo BW one d post injection, and increased absolute and relative (percentage of set egg weight) chick BW 3 d post injection. The absence of an effect on BW at hatch in this study, which is in contrast to the increases in embryo BW and chick BW at 3 dph that were observed by Zhai et al. (2011) , may be due to the fact that a much smaller volume (4.2%) of fluid was injected in this study in comparison to that injected by Zhai et al. (2011) .
By 7 dph, a significant (P = 0.028) effect due to treatment on BW was nevertheless observed, in which the BW of broilers in the diluent-injected control group was higher than that of those in the non-injected control group, with those in the dry-punch and vaccine-injected groups being intermediate. The significant (P = 0.022) treatment effects on BWG between zero and 7 dph were the same as those for BW at 7 dph, with the treatment differences in BWG being associated with significant (P = 0.002) treatment differences in FI between zero and 7 dph (Table 1) . However, when compared to birds in the diluent-injected control group, the numerical decrease in the zero to 7 dph BWG of birds in the drypunch control group was related to a significant decrease in their zero to 7 dph FI. Notwithstanding, the close positive relationship between FI and BWG between zero and 7 dph resulted in the lack of any significant (P = 0.126) treatment effects on FCR in that dph interval (Table 1) .
The diluent used in this study is widely used commercially as a carrier for the Marek's disease vaccine. Although the precise constitution of the commercial diluent is proprietary, the diluent could increase the relative water content of the bodily tissue of the birds, as well as provide the embryo and chick with supplemental nutrients that may stimulate growth. These factors have the potential to increase chick BW at hatch and to Table 1 . Growth performance parameter means in the non-injected, dry-punch, and diluent-injected control groups, and in the vaccine-injected treatment group. enhance post-hatch growth performance. A relationship is known to exist between water and feed consumption in growing broilers (May and Lott, 1992) . Therefore, the preclusion of a possible hydration effect in the birds belonging to the dry-punch control group may in part be the basis for a decrease in their subsequent posthatch FI. Despite not having a more immediate effect on hatchling BW, the results of the current study suggest that the addition of 50 μL of diluent to the amnion, through the possible individual or combined effects of increased hydration or nutrient availability, may have eventually promoted growth during the first wk of the post-hatch period, but that inclusion of the EM1 vaccine in the diluent diminished this effect. These results more specifically suggest that when compared to birds belonging to the non-injected group, in ovo administration of the EM1 vaccine did not cause a significant change in BW during peak oocyst shedding (7 dph).
As was observed at 7 dph, treatment also significantly (P = 0.006) affected BW at 14 dph. Treatment effects that were analogous to those at 7 dph continued to be observed for BW at 14 dph. The noted treatment effects on BW at 14 dph, however, were slightly different, in that the BW of birds belonging to the vaccine-injected group were significantly higher in comparison to birds in the non-injected control group. Similar treatment effects on BW at 7 and 14 dph resulted in a treatment response for 7 to 14 dph BWG that corresponded with that for zero to 7 d BWG. In the zero to 7 and 7 to 14 dph intervals, the BWG of birds in the diluentinjected control group was significantly higher than that of those in the non-injected control group, with those in the dry-punch control and vaccine-injected groups being intermediate. Furthermore, the effects of treatment on zero to 14 d BWG resembled those for BWG in both the zero to 7 and 7 to 14 dph intervals, except that zero to 14 dph BWG in the vaccine-injected treatment group was significantly higher than that in the non-injected control group (Table 1) .
Treatment significantly affected the FI of birds in the 7 to 14 (P = 0.0005) and entire zero to 14 (P = 0.0002) dph periods. The positive association between BWG and FI that was observed in the zero to 7 dph age interval continued into the 7 to 14 dph period as well as the overall zero to 14 dph age interval. As in the zero to 7 dph period, FI in the 7 to 14 and zero to 14 dph periods was higher in the diluent-injected control group in comparison to that in the dry-punch and non-injected control groups. In an investigation of the post-hatch performance of broilers, Bello et al. (2014) noted that the zero to 7, 7 to 14, 14 to 21, zero to 21, 21 to 28, 28 to 35, 35 to 42, 42 to 48, or zero to 48 dph BWG of birds in a non-injected control group was not significantly different from a group administered 100 μL of commercial diluent by in ovo injection. There were also no noted significant effects on FI or FCR in any of those age intervals. Even though these potential effects were not observed by Bello et al. (2013 Bello et al. ( , 2014 , they were nevertheless observed in the current study. The lower volume of diluent used in this study and the commonality of broiler strain and diluent used in this and the previous studies make these differences difficult to explain. Nonetheless, the current results indicate that effects of the diluent delivered by in ovo injection on broiler performance may persist through 14 dph.
Live vaccines for the control of coccidiosis have been employed in meat-type birds up to 56 or more dph (Chapman, 2000) , and are now currently used in the commercial broiler industry. Chapman et al. (2002) reported that the use of a coccidiosis vaccine (Coccivac-B; Schering Plough, Kenilworth, NJ) delivered within a spray cabinet as an aqueous suspension had no deleterious effects in commercial broilers. However, in a later report using the same brand of vaccine as was used by Chapman et al. (2002) , Walk et al. (2011) showed that spray vaccination of the vaccine resulted in a significant reduction in the FI and BWG of broilers from zero to 18 dph in association with peak vaccine oocyst infection. In comparison to non-vaccinated birds, Parker et al. (2007) also observed a significant transient reduction in the FI and BWG of broilers between zero and 17 dph after having been spray-vaccinated with live oocysts at hatch. More recently, Wang et al. (2016) likewise observed that administering a commercial live coccidial spray vaccination at hatch decreased the zero to 14 and 29 to 42 dph BWG of male broilers. Nevertheless, Weber et al. (2004) showed that the BWG of chicks immunized with 1 × 10 5 sporulated E. praecox delivered by in ovo injection was not significantly different from that of non-immunized birds through 14 dph. Chapman et al. (2002) have summarized that the oocysts of various Eimeria species can be safely administered by in ovo injection and can be used to confer effective protection against challenge infections. These present results also further clearly indicate that in ovo vaccination of Ross 708 broilers with the EM1 vaccine suspended in 50 μL of commercial diluent does not adversely affect their growth performance, but may provide some benefit. In the 7 to 14 and zero to 14 dph periods of the present investigation, FI in the vaccine-injected birds was significantly greater than that of the non-injected control birds. In contrast to the zero to 7 dph age interval, FCR in the 7 to 14 (P = 0.043) and zero to 14 (P = 0.036) dph periods was also significantly affected by treatment. However, the FCR in both periods were higher in the diluentinjected control group of birds than in the non-injected control group, with the dry-punch control and vaccineinjected treatment group being intermediate (Table 1) . This indicates that despite the fact that feed efficiency in those age intervals was worse for birds in the diluentinjected group than for those in the non-injected group, feed efficiency was not compromised by inclusion of the EM-1 vaccine in the diluent. In accordance with the previous results of Sokale et al. (2017) , showing that in ovo injection of the EM1 vaccine suspended in 50 μL of commercial diluent at 18.5 doi had no detrimental effect on hatchability or hatchling quality, it also was concluded upon observance of the results of this current study that its use likewise had no detrimental effect on the post-hatch survivability or 14 d grow-out performance of Ross 708 broilers.
